Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ImmuCell Corp ICCC

Healthcare Biotechnology
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which... see more

Recent & Breaking News (NDAQ:ICCC)

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020

GlobeNewswire October 6, 2020

ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2020

GlobeNewswire August 12, 2020

ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020

GlobeNewswire August 6, 2020

ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020

GlobeNewswire July 7, 2020

ImmuCell Receives $500,000 Loan from the Maine Technology

GlobeNewswire June 16, 2020

ImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference

PR Newswire May 14, 2020

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

GlobeNewswire May 14, 2020

ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2020

GlobeNewswire May 13, 2020

ImmuCell to Announce Unaudited Financial Results for First Quarter of 2020

GlobeNewswire May 7, 2020

ImmuCell Receives $938,000 in Support under the Paycheck Protection Program

GlobeNewswire April 14, 2020

ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020

GlobeNewswire April 2, 2020

ImmuCell Announces Refinancing of its Bank Debt

GlobeNewswire March 11, 2020

ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019

GlobeNewswire February 19, 2020

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2019

GlobeNewswire February 18, 2020

ImmuCell to Announce Preliminary Financial Results for the Year Ended December 31, 2019

GlobeNewswire February 13, 2020

ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019

GlobeNewswire January 21, 2020

ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

GlobeNewswire November 11, 2019

ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

GlobeNewswire November 5, 2019

ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain(TM)

GlobeNewswire September 11, 2019

ImmuCell Receives FDA Response To First CMC Submission for Re-Tain(TM)

GlobeNewswire August 29, 2019